JCC 4/6/2023

# CURRICULUM VITAE

**NAME:** Campbell, Jr., Joseph, Clyde | **DATE:** 06/APR/2023

**POSITION TITLE:** Investigator


**OFFICE ADDRESS:**
Spectrum Medical, Inc.
109 Bridge Street, Suite 300
Danville, VA 24541 USA

**CONTACT INFORMATION:**
Telephone: (434)793-4711
Fax: (434)792-5265
e-Mail: joseph.campbell@spectrummed.com


**PROFESSIONAL LICENSURE:** Commonwealth of Virginia Board of Medicine #0101047576, USA

**BOARD CERTIFICATIONS (if applicable):** 1999-present American Board of Orthopaedic Surgery, USA

**DEA LICENSE NUMBER (IF APPLICABLE):** *DEA#BC 6219718*

**EDUCATION/TRAINING:** *(Include baccalaureate or other initial professional education such as nursing, postdoctoral training, GCP training.)*

| INSTITUTION AND LOCATION | DEGREE *(if applicable)* | YEAR(s) | FIELD OF STUDY |
|---|---|---|---|
| National Naval Medical Center, Bethesda, Maryland, USA | Residency | 1993-1997 | Orthopedic Surgery |
| National Naval Medical Center, Bethesda Maryland, USA | Internship | 1990-1991 | Surgery |
| University of Virginia | Doctor of Medicine | 1990 | MD |
| Washington & Lee University | B.A. | 1986 | B.A. Chemistry |

**Specialization:** Orthopedic Surgery

**POSITIONS AND EMPLOYMENT:**

1999-present Orthopedic Surgeon, Spectrum Medical, Inc. (formerly Danville Orthopedic Clinic, Inc.), Danville, Virginia, USA
1997-1999 Orthopedic Staff Surgeon, Naval Hospital Camp Lejeune, North Carolina, USA
1991-1993 General Medical Officer, Active Military Duty U.S. Navy (USS El Paso LKA-117), USA

**OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS:**

1999-present Fellow of American Academy of Orthopedic Surgeons
1999-present American Medical Association, Member

**RESEARCH EXPERIENCE:**

A **Phase 3,** Multicenter, randomized, placebo controlled, double-blind, 22 week and 30 week open label study to evaluate the efficacy, safety, and PK of XXX Spray in relief of the pain for subjects with Osteoarthritis of the knee. Role: Sub Investigator 10/21- Present

A **Phase 3,** 14-Day, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Multicenter Study of the Efficacy and Safety of XXX in subjects with pain due to Acute Back Muscle Spasm. (2020-2/2022). Role: Principal -Investigator

A phase 3 Prospective, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of XXX in in patients with osteoarthritis of the knee.(12/2020-Present) Role: Sub- Investigator. Injectable OA knee.

Phase 2, Randomized, Double-Blind, Placebo Controlled study of the safety and efficacy of XXX for the treatment of adhesive Capsulitis of the Shoulder (2020-2022) Role: Sub-Investigator

A Randomized, Double-Blind, Placebo-Controlled, Multi-center Pilot Study of a Single Injection XXX Combined with YYY to Provide Symptomatic Relief of OA of the Knee. Phase 2.(2020-2022)
Role: Sub Investigator

A Randomized, Double-Blind, Placebo Controlled, Parallel group study to evaluate the efficacy and safety of XXX in patients with Hip Osteoarthritis. (2019-2020). Role: Sub Investigator

A Randomized, Double-Blind, Placebo controlled, 2-injection, 52 week study to evaluate the efficacy and safety of Intra-articular injections of XXX in subjects with chronic, Moderate-to Severe osteoarthritis knee pain. (Jan 2019-2021). Role: Sub Investigator

A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women with Osteoporosis to Evaluate the Non-inferiority of subjects administered XXX via auto injector/pen vs. Healthcare provider administered XXX via prefilled syringe. (Jan 2018-2019). Role: Sub-Investigator.

A Phase 4, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of XXX in combination with XOI compared with XOI alone, in subjects with Gout and Estimated Creatinine Clearance 30 to <60 mL/min who have not achieved target serum uric acid levels on an XOI Alone. (Aug 2017-Feb 2019). Role: Principal-Investigator.

A **Phase 3**, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the analgesic efficacy and safety of a dose titration regiment for the subcutaneous administration of XXX in subjects with osteoarthritis of the hip of knee. (2016-2018). Role: Sub Investigator.

A **Phase 2A**, Randomized, Double-Blind, Placebo Controlled crossover study of the Safety and Efficacy of XXX in subjects with Osteoarthritis of the knee. (2016-2016). Role: Sub Investigator.

Prospective, Multi-Center, Randomized, Three–Arm, Parallel group, clinical study to evaluate the superiority of 3 weekly intra-articular doses of 2ml of Investigational Product as compared to Placebo and XXXX injected into the target knee for the treatment of pain in subjects with Osteoarthritis.
(2015) Role: Sub-Investigator. **Device Study.**

Double Blind, Placebo-controlled, Randomized, Parallel–group Study to Determine the Safety and Efficacy of a Topical Patch (XXXX) Following Daily Administration for 2 Weeks in Patients with Chronic Low Back Pain. **Phase 2.** (2015-2015) Role: Principal Investigator

A Randomized, Sham-Controlled Pilot Study of XXXX Therapy in the Treatment of Persistent Post-Operative Pain following a Total Knee Arthroplasty (**Device Study**). (2015-2016). Role: Sub-Investigator

A **Phase 3**, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of XXX , XXX, XXX, XXX in Subjects with Gout. (2014-2016).
Role: Principal-Investigator

A Randomized, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of a single intra-articular injection of XXX in adults with pain due to osteoarthritis of the knee. (1/2014- 10/2014). **Phase 3.** Role- Sub-Investigator.

A Randomized, Double-Blind, Multiple Center, Placebo Controlled Study Comparing the Safety and Efficacy of a Multiple Dose of Generic XXX to YYY in the Treatment of Acute Pain Due to Minor Ankle Sprain. (May 2014-October 2014). **Phase: 3**. Role: Sub Investigator.

A Double-Blind, Randomized, Parallel Group, Dose Ranging Study to Assess the Efficacy and Safety of XXX for the Treatment of pain in Patients with Osteoarthritis of the knee. (March 2014-2015). **Phase: 2**.Role: Sub Investigator

A Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of XXX for the Treatment of Adhesive Capsulitis of the Shoulder. (12/2013-2/2015). Role: Sub-Investigator.

Placebo Controlled, Double Blind Evaluation of the Efficacy and Safety of XXX for the treatment of Ankle Sprain. (Nov. 2013-April 2015). Role: Sub Investigator.

A Randomized, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of intra-articular injection of XXX in adults with pain due to osteoarthritis of the knee. (April 2013-August 2013). Role- Sub-Investigator.

A Randomized, Double-Blind, Double Dummy, Placebo Controlled, Active Controlled, Parallel Group, Multicenter Trial of XXX to Assess the Analgesic Efficacy and the Management of Opioid Induced Constipation in Subjects with Moderate to Severe Chronic Low Back Pain and a history of OIC. (November 2012-December 2014). Principal Investigator

A Randomized, Double-Blind, Multicenter, Placebo Controlled, Combination Study to Evaluate the Efficacy and Safety of XXX and YYY compared to YYY Alone in Lowering Serum Uric Acid and Resolving Tophi in Subjects with Tophaceous Gout.(March 2012- 2015). Phase 3. Role: Principal-Investigator

A Randomized, Double-Blind, Multicenter, Placebo Controlled, Combination Study to Evaluate the Efficacy and Safety of XXX and YYY compared to YYY Alone in Subjects with Gout who had an inadequate hypouricemic response to Standard of Care YYY.(March 2012- 2015). Phase 3. Role: Prinicpal-Investigator

A Randomized, double Blind, active controlled study of XXX prefilled syringes or XXX reconstituted lyophilizate or YYY for treating acute gouty arthritis flares in frequently flaring patients. Phase 3. (5/2011-2013). Role: Principal Investigator

A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of XXX vs placebo on Renal Function in Gout Subjects with Hyperuricemia and Moderate to Severe Renal Impairment. Phase 2.
(4/2011-2012). Role: Principal Investigator

A Multicenter, Randomized, Active Control, Phase 3B Study to Evaluate the Cardiovascular Safety of XXX and YYY in Subjects with Gout and cardiovascular Co-morbidities. Phase 3B. (3/2011-2017). Role: Principal Investigator

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III trial to Evaluate the Efficacy, Tolerability, and Safety of XXX in the Treatment of Tendonitis and Bursitis of the shoulder.
(2010-2011). Role: Sub-Investigator

A Randomized, Multi-center, Double-Blind, Factorial, Comparator and Placebo-Controlled Phase III trial to Evaluate the Efficacy, Tolerability, and Safety of XXX in the Treatment of Ankle Sprains. (2010-2011). Role: Sub-Investigator

Phase III, Randomized, controlled study of XXX on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDS and/or colchicine are contraindicated, not tolerated or ineffective. (2010) Role: Principal Investigator

A randomized, double blind, placebo controlled study to determine the efficacy of XXX in the treatment of pain caused by osteoarthritis of the knee. Phase III. Role: Sub Investigator

A randomized, Multicenter, Double-Blind, Placebo controlled study to evaluate the Efficacy and Safety of XXX in the treatment of pain associated with mild to moderate ankle sprain. Phase III. (2009-2010). Role: Sub-Investigator

Observational Registry of Patients Using Prescription Medications Containing XXX for the treatment of pain. Phase 4. Role: Principal Investigator

Phase III, Open Label, Randomized, Referred Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of XXX on Vitamin D Adequacy in the Treatment of Osteoporosis in Postmenopausal Women.(2008-2010). Role: Sub Investigator

Study for the validation of XXX for Assessing Opioid-Induced Constipation/ Device Study (2008-2009)Role: Principal Investigator

A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of three injections of XXX For the treatment of Chronic Shoulder Pain Associated with Glenohumeral Osteoarthritis. (2008-2010). Role: Sub Investigator

A Phase III, Flexible-Dose Titration Followed by a Randomized Double Blind Study of Controlled Release XXX Compared to Placebo in Patients with Osteoarthritis Pain (2008). Opioid Study. Role: Principal Investigator

A Randomized, Open Label, Blinded-Endpoint, Parallel Group Trial of GI Safety of XXX compared with NSAIDS in Osteoarthritis Patients . (2007-2010). Role: Sub-Investigator

Open Label Extension, Single Arm, Flexible Dosing, Phase III Trial with XXX in Subjects with Moderate to Severe Chronic Pain. (2008-2009). Opioid Study. Role: Principal Investigator

A Randomized, Double-Blind, Active- And Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of XXX In Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease. (2007). Opioid Study Role: Principal Investigator

A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular Disease Comparing XXX with YYY and ZZZ.(2006-2016). Role: Sub-Investigator.

A Six week Double-blind, Randomized, Multi-center comparison Study of the analgesic effectiveness of XXX compared to YYY In Subjects with Chronic Low Back Pain. (2006) Role: Sub-Investigator.

Observational study of men and women with osteoporosis who have been Prescribed XXX. (2004-2010)

Role: Sub-Investigator.

Multinational, multicenter, double-blind, randomized, placebo-controlled, parallel group study assessing the efficacy of intravenous XXX in preventing subsequent osteoporotic fractures after a hip Fracture. (2002-2007). Role: Sub-Investigator.

A randomized, double-blind, Active-comparator controlled, Parallel Group study to evaluate the safety of XXX in patients with Osteoarthritis Or Rheumatoid Arthritis. (2002-2006). Role: Sub-Investigator.

# Virginia Department of Health Professions
# License Lookup

Current as of 12/21/2022 08:34

## License Information

| | |
|---|---|
| **License Number** | 0101047576 |
| **Occupation** | Medicine |
| **Name** | Joseph C Campbell Jr. |
| **Address** | Danville, VA 24541 |
| **Initial License Date** | 12/31/1991 |
| **Expire Date** | 11/30/2024 |
| **License Status** | Current Active |
| **Additional Public Information*** | No |

Back to License Lookup Result

**This serves as primary source verification of the credential issued by the Commonwealth of Virginia and meets the requirements of the Joint Commission.**

** "Yes" means that there is information the Department must make available to the public pursuant to §54.1-2400.2.H of the Code of Virginia; please note that this may also include proceedings in which a finding of "no violation" was made. For additional information click on the "Yes" link above. "No" means no documents are available.*

Back to License Lookup